glp-1 approved for weight loss The New Management Meds Harnessing GLP-1 Receptor Agonists for

Glucagon-like peptide-1 (GLP-1) is an incretin hormone produced by enteroendocrine L-cells in the distal small intestine and colon in response to nutrient intake

As such, GLP-1RAs have become the most widely prescribed anti-obesity agents worldwide [8, 9]

doi: 10.1038/nm1197

Clinical safety profile Common Adverse Effects The most frequent adverse effects associated with SSRI therapy include sexual dysfunction, GI symptoms, cognitive slowing, and sleep disruption, which collectively affect patient quality of life and treatment adherence

GLP-1 receptor agonists slow gastric motility, which means food moves through your digestive tract more slowly